SIRPA and neoplasm: Blocking this checkpoint through antibodies, fusion proteins, or genetic deletion (e.g., SIRPα-deletion) has been shown in preclinical models to enhance phagocytosis, promote M1 polarization, and improve tumor clearance (17, , , –21).